Achieve Life Sciences' NDA for cytisinicline received a Complete Response Letter (CRL) from the FDA.

2 reports, 1 independent Updated Aug 11

Gone quiet Reached 2 outlets in its first 24 hours

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Achieve Life Sciences' NDA for cytisinicline received a Complete Response Letter (CRL) from the FDA.

Who's involved

What this event is mainly about

FDA

Keep exploring

Part of

Achieve Life Sciences is seeking FDA approval for its cytisinicline drug, and HC Wainwright has initiated coverage with a Buy rating. All 1 developments

The entities involved

FDA
- NRx Pharmaceuticals is undergoing a first-cycle review of an ANDA for ketamine, noting its strategic importance for the U.S. military and VA.19:54
- BridgeBio announced on August 14, 2026, that it has submitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA).17:22

Related events

Coverage

Newest first; wire copies grouped

Aug 11finanznachrichten.de

1 more outlet ran the same wire story

Aug 11manilatimes.net